Acasti Pharma (CVE:ACST) Stock Price, News, Analysis & History

C$1.40 +0.01 (+0.72 %)
(As of 03/22/2018 04:00 PM ET)
Previous CloseC$1.39
Today's RangeC$1.38 - C$1.43
52-Week RangeC$1.07 - C$2.99
Volume19,530 shs
Average Volume51,447 shs
Market CapitalizationC$33.54 million
P/E Ratio-1.19
Dividend YieldN/A

About Acasti Pharma (CVE:ACST)

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.

Receive ACST News and Ratings via Email

Sign-up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio-1.18803418803419
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSC($1.17)
Net IncomeN/A
Net MarginsN/A
Return on Equity-162.34%
Return on Assets-103.36%


Outstanding Shares25,605,000

Acasti Pharma (CVE:ACST) Frequently Asked Questions

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ACST."

Who are some of Acasti Pharma's key competitors?

Who are Acasti Pharma's key executives?

Acasti Pharma's management team includes the folowing people:

  • Roderick Noel Carter, Executive Chairman of the Board
  • Janelle D'Alvise, President, Chief Executive Officer, Director
  • Linda Parinella O'Keefe, Chief Financial Officer
  • Pierre Lemieux Ph.D., Chief Operating Officer
  • Laurent Harvey, Vice President- Clinical and Non-Clinical Affairs
  • Jean-Daniel Belanger, Secretary, Director- Corporate Affairs
  • Jean-Marie Canan, Director (Age 61)

Has Acasti Pharma been receiving favorable news coverage?

Media coverage about ACST stock has trended positive on Thursday, according to Accern Sentiment. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Acasti Pharma earned a media sentiment score of 0.27 on Accern's scale. They also assigned news coverage about the company an impact score of 44.55 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Acasti Pharma?

Shares of ACST and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately C$1.40.

How big of a company is Acasti Pharma?

Acasti Pharma has a market capitalization of C$33.54 million.

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada. The company can be reached via phone at +1-450-6864555.

MarketBeat Community Rating for Acasti Pharma (ACST)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  73
MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Acasti Pharma (CVE:ACST) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Earnings History for Acasti Pharma (CVE:ACST)

No earnings announcements for this company have been tracked by


Acasti Pharma (CVE:ACST) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Acasti Pharma (CVE:ACST)

No dividend announcements for this company have been tracked by

Insider Trades

Acasti Pharma (CVE ACST) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Acasti Pharma (CVE:ACST)

Acasti Pharma (CVE ACST) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2017Jean-Daniel BélangerDirectorSell51,199C$2.41C$123,389.59
(Data available from 1/1/2013 forward)


Acasti Pharma (CVE ACST) News Headlines


SEC Filings

Acasti Pharma (CVE:ACST) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Acasti Pharma (CVE ACST) Stock Chart for Thursday, March, 22, 2018

Loading chart…

This page was last updated on 3/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.